ArticleAnnals of medicine and surgery (2012)2026
Insights into the pathophysiology of stroke-heart syndrome: a review of recent literature and clinical trials to illuminate promising therapeutic strategies.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke heart syndrome (SHS) represents a complex interplay between cerebrovascular and cardiovascular pathophysiology, leading to significant morbidity and mortality. This review explores the mechanisms underlying SHS, highlighting neurogenic, inflammatory, and hemodynamic interactions that contribute to myocardial injury, arrhythmias, and heart failure post-stroke. A detailed examination of risk factors, including hypertension, atrial fibrillation, and metabolic disorders, underscores their role in predisposing individuals to SHS. The clinical manifestations of SHS, ranging from acute coronary syndromes to neurogenic cardiac injury, are reviewed, along with key diagnostic tools such as cardiac biomarkers, electrocardiographic changes, and imaging modalities. Emerging therapeutic strategies, including neuroprotective interventions, anticoagulation, and cardioprotective agents, are discussed in the context of optimizing patient outcomes. The integration of multidisciplinary care approaches, involving both neurologists and cardiologists, is crucial for mitigating the adverse consequences of SHS. Future research should focus on refining risk stratification models, developing targeted interventions, and exploring novel biomarkers to enhance the management of SHS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.